Ellis F H, Heatley G J, Balogh K
Division of the Cardiothoracic Surgery, Deaconess Hospital, Boston, MA 02215, USA.
Eur J Cardiothorac Surg. 1997 Sep;12(3):361-4; discussion 364-5. doi: 10.1016/s1010-7940(97)00178-4.
Current staging for carcinoma of the esophagus and cardia remains imprecise. In an effort to improve on presently accepted staging criteria, new and improved criteria were sought.
A total of 408 specimens resected for carcinoma of the esophagus or cardia between January 1, 1970, and January 1, 1994, were available for analysis. Pathology reports were reviewed, and available histologic slides were examined microscopically. When necessary, paraffin blocks of excised specimens were recut for further pathologic evaluation. On the basis of these findings, tumors were staged according to the criteria of American Joint Committee on Cancer (AJCC). New criteria were established based on the WNM concept and staged accordingly. Survival rates based on these sets of criteria were calculated for each stage, and results were compared.
Because our previous studies had shown no advantage provided by the revised AJCC criteria compared with those originally proposed, we modified the WNM system by eliminating the subdivisions of Stage II, reducing the T categories by 1, T3 and T4 having shown no survival differences, and increasing the N categories by 1, depending on the number of nodes involved, e.g. NO = no positive nodes; N1 = 1-4 positive nodes, and N2-5 or more positive nodes. The resulting staging system and 5-year survival rates obtained thereby are as follows: Stage O (TO, is, 1 NO), 88.2%; Stage I (T1N1, T2NO), 50.3%; Stage II (T2N1, T3N0) 22.5%; Stage III (T3N1, any T N2), 10.7%; and Stage IV (M1) 0%.
A new staging scheme for carcinoma of the esophagus and cardia is proposed that provides better prognostic stratification of patients than existing ones.
目前食管癌和贲门癌的分期仍不准确。为改进当前公认的分期标准,探寻新的改良标准。
1970年1月1日至1994年1月1日期间共408例因食管癌或贲门癌切除的标本可供分析。回顾病理报告,并对现有组织学切片进行显微镜检查。必要时,重新切取切除标本的石蜡块进行进一步病理评估。根据这些结果,依据美国癌症联合委员会(AJCC)的标准对肿瘤进行分期。基于WNM概念建立新的标准并相应分期。计算各分期基于这两套标准的生存率,并比较结果。
由于我们之前的研究表明,修订后的AJCC标准与最初提出的标准相比并无优势,我们对WNM系统进行了修改,取消了Ⅱ期的细分,将T分类减少1级,因为T3和T4显示无生存差异,将N分类增加1级,根据受累淋巴结数量而定,例如,N0 = 无阳性淋巴结;N1 = 1 - 4个阳性淋巴结,N2 = 5个或更多阳性淋巴结。由此得到的分期系统及5年生存率如下:0期(T0,is,N0),88.2%;Ⅰ期(T1N1,T2N0),50.3%;Ⅱ期(T2N1,T3N0),22.5%;Ⅲ期(T3N1,任何T N2),10.7%;Ⅳ期(M1),0%。
提出了一种新的食管癌和贲门癌分期方案,与现有方案相比,能更好地对患者进行预后分层。